Small-molecule drugs for cystic fibrosis: Where are we now?

Autor: Laselva O; Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Guerra L; Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy., Castellani S; Department of Medical Sciences and Human Oncology, University of Bari, Bari, Italy., Favia M; Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy., Di Gioia S; Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Conese M; Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. Electronic address: massimo.conese@unifg.it.
Jazyk: angličtina
Zdroj: Pulmonary pharmacology & therapeutics [Pulm Pharmacol Ther] 2022 Feb; Vol. 72, pp. 102098. Date of Electronic Publication: 2021 Nov 15.
DOI: 10.1016/j.pupt.2021.102098
Abstrakt: The cystic fibrosis (CF) lung disease is due to the lack/dysfunction of the CF Transmembrane Conductance Regulator (CFTR), a chloride channel expressed by epithelial cells as the main regulator of ion and fluid homeostasis. More than 2000 genetic variation in the CFTR gene are known, among which those with identified pathomechanism have been divided into six mutation classes. A major advancement in the pharmacotherapy of CF has been the development of small-molecule drugs hitting the root of the disease, i.e. the altered ion and fluid transport through the airway epithelium. These drugs, called CFTR modulators, have been advanced to the clinics to treat nearly 90% of CF patients, including the CFTR potentiator ivacaftor, approved for residual function mutations (Classes III and IV), and combinations of correctors (lumacaftor, tezacaftor, elexacaftor) and ivacaftor for patients bearing at least one the F508del mutation, the most frequent mutation belonging to class II. To cover the 10% of CF patients without etiological therapies, other novel small-molecule CFTR modulators are in evaluation of their effectiveness in all the CFTR mutation classes: read-through agents for Class I, correctors, potentiators and amplifiers from different companies for Class II-V, stabilizers for Class VI. In alternative, other solute carriers, such as SLC26A9 and SLC6A14, are the focus of intensive investigation. Finally, other molecular targets are being evaluated for patients with no approved CFTR modulator therapy or as means of enhancing CFTR modulatory therapy, including small molecules forming ion channels, inhibitors of the ENaC sodium channel and potentiators of the calcium-activated chloride channel TMEM16A. This paper aims to give an up-to-date overview of old and novel CFTR modulators as well as of novel strategies based on small-molecule drugs. Further investigations in in-vivo and cell-based models as well as carrying out large prospective studies will be required to determine if novel CFTR modulators, stabilizers, amplifiers, and the ENaC inhibitors or TMEM16A potentiators will further improve the clinical outcomes in CF management.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: